Sabrina Ahle

Associate Managing Editor

Articles by Sabrina Ahle

Sabrina AhleMyeloma | November 14, 2022
New legislation would set time limits around FDA accelerated approvals.
Sabrina AhleAcute Myeloid Leukemia | February 2, 2023
The designation was granted to ex vivo investigational T-cell receptor therapy NTLA-5001.
Sabrina AhleAcute Myeloid Leukemia | February 2, 2023
The FDA has accepted the sNDA for ivosidenib tablets as a proposed treatment for previously untreated IDH1-mutated AML.
Sabrina AhleAcute Lymphoblastic Leukemia | February 2, 2023
The FDA has published draft recommendations for potential manufacturers of gene therapy products.
Sabrina AhleAcute Myeloid Leukemia | February 2, 2023
Mocravimod is a sphingosine 1 phosphate receptor modulator.
Sabrina AhleChronic Myeloid Leukemia | November 14, 2022
Researchers shared additional data on the immune response of patients with chronic myeloid leukemia to COVID-19 infection and ...
Sabrina AhleChronic Myeloid Leukemia | November 22, 2022
At least one-quarter of patients experienced arterial occlusive events (AOE), but rates varied depending on the approach.
Sabrina AhleChronic Myeloid Leukemia | November 14, 2022
Researchers surveyed the reasons for low recruitment and early closure of the UK National Cancer Research Institute’s ...
Sabrina AhleMyelofibrosis | April 12, 2023
The FDA has granted accelerated approval to pacritinib for the treatment of adult patients with intermediate or high-risk.
Sabrina AhleChronic Lymphocytic Leukemia | February 2, 2023
Many side effects of the COVID-19 pandemic have disproportionately impacted older Americans.
Sabrina AhleMyeloma | November 14, 2022
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Sabrina AhleHodgkin Lymphoma | March 12, 2022
Oxford Biodynamics has announced the US launch of the clinical blood test.
Sabrina AhleMyeloma | November 14, 2022
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Sabrina AhleAcute Myeloid Leukemia | February 2, 2023
The EU proposed the first international regulation for artificial intelligence.
Sabrina AhleHodgkin Lymphoma | November 14, 2022
Researchers examined survival rates by age in patients with Hodgkin lymphoma receiving response-adapted therapy on ...
Sabrina AhleMyeloproliferative Neoplasms | May 30, 2023
In patients with high-risk essential thrombocythemia and polycythemia vera, both hydroxyurea and pegylated interferon-α.
Sabrina AhleMantle Cell Lymphoma | February 1, 2023
A recent study of brexu-cel supports its use for the treatment of MCL.
Sabrina AhleMyeloma | November 14, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Sabrina AhleIndolent B-Cell Lymphoma | November 14, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Sabrina AhleIndolent B-Cell Lymphoma | November 14, 2022
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...